Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy

Saudi Medical Journal

Volumn 29, Issue 2, 2008, Pages 185-192

  Alghasham, Abdullah A ^a   Barakat, Youssef A ^a  

^a QASSIM UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; VISFATIN;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY MASS; BODY WEIGHT; COLORIMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC ANGIOPATHY; DIABETIC DIET; DIABETIC OBESITY; DIABETIC PATIENT; DIET RESTRICTION; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; SAUDI ARABIA;

ADULT; ANGINA, UNSTABLE; BODY MASS INDEX; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; STROKE; VASCULAR DISEASES;

EID: 40749154413     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis epidemiology, pathophysiology and management. JAMA 2002: 287: 2570-2581.
2. Reusch JE, Draznin BB. Atherosclerosis in diabetis and insulin resistance. Diabetes Obes Metab 2007; 9: 455-463.
3. Ginsberg H. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-458.
4. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005; 54: 1615-1625.
5. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
6. Ridker PM. High-sensitivity C-reactive protein potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1818.
7. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
8. Kaperonis EA, Liapis CD, Kakisis JD, Dimitroulis D, Papavassiliou VG. Inflammation and Atherosclerosis. Eur J Vasc Endovasc Surg 2006; 31: 386-393.
9. Wajchenberg BL. Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738.
10. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 2004; 89: 2601-2607.
11. Despres JP. Health consequences of visceral obesity. Ann Med 2001; 33: 534-541.
12. Dandona P, Aljada A. Bandyopathy A. Inflammation: The link between insulin resistance, obesity and diabetes. TRENDS Immunol 2004; 25: 4-7.
13. Arner P. Insulin resistance in type 2 diabetes-role of the adipokines. Curr Mol Med 2005; 5: 333-339.
14. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-919.
15. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: Molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005; 288: 2031-2041.
16. Samal B, Sun Y, Stearns G, Xie C, Suggs C, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994; 14: 1431-1437.
17. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430
18. Kloting N, klothing I. Visfatin: Gene expressoin in isolated adipocytes and sequence analysis in obese WOKW rats compared with lean control rats. Biochem Biophys Res Commun 2005; 332: 1070-1072.
19. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 2005; 185: 1-8.
20. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, et al. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2005; 289: 586-590.
21. Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 2007; 56: 565-570.
22. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003: 26: S5-S20.
23. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation and treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, MD: National Institutes of Health 1998. NIH publication 98-4083. Available from URL: Http://www.nhlbi.nih.gov./guidelines/obesity/ob_gdlns.pdf.
24. Friedewald WT, Levry RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985: 28: 412-419.
26. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Prac 2007; 76: 24-29.
27. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299.
28. Jian WX, Luo TH, Gu YY, Zhang HL, Zheng S, Dai M. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet Med 2006; 23: 967-973.
29. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-2916.
30. Chan TF, Chen YL, Lee CH, Chou FH, Wu LC, Jong SB, et al. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Investig 2006; 13: 364-367.
31. Stephens JM, Vidal-Puig AJ. An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulafted in obesity. Curr Opin Lipidol 2006; 17: 128-131.
32. Pagano C, Pilon C, Oliveri M, Mason P, Fabris R, Serra R, et al. Reduced plasma visfatin/pre-B cell colony enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006; 91: 3165-3170.
33. Smith J, Al-Amri M, Sniderman A, Cianflone K. Visfatin concentration in Asian Indians is correlated with high density lipoprotein cholesterol and apolipoprotein A1. Clin Endocrinol 2006; 65: 667-672.
34. Sethi JK, Vidal-Puig A. Visfatin: The missing link between intraabdominal obesity and diabetes? Trends Mol Med 2005; 11: 344-347.
35. Curat CA, Wegner V, Sengenès C, Miranville A, Tonus C, Busse R, et al. Macrophages in human visceral adipose tissue: Increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744-747.
36. Ye SQ, Simon BA, Maloney JP, Zambelli-Weiner A, Gao L, Grant A. Pre-B-cell colony-enhancing factor as a potential novel biomaker in acute lung injury. Am J Respir Crit Care Med 2005; 171: 361-370.
37. Jia Sh, Li Y, Parodo J. Kapus A, Fan L, Rotstein OD. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 1318-1327.
38. Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee MJ, et al. Human visfatin expression: Relationship to insulin sensitivity, intramyocellular Lipids, and inflammation. J Clin Endocrinol Metab 2007; 92: 666-672.
39. Seo JA, Jang ES, KIm BG, Ryu OH, Kim HY, Lee KW, et al. Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women. Diabetes Res Clin Pract 2007; [Epub ahead of print].
40. Oki K, Yamane K, Kamei N, Nojima H, Kohno K. Circulating visfatin level is correlated with inflammatio, but not with insulin resistance. Clin Endocrinol 2007; 67: 796-800.
41. MacLaren R, Cui W, Cianflone K. Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes Obes Metab 2007; 9: 490-497.
42. Hausenloy DJ, Lim SY, Paramanathan AJ, Davidson SM, Yellon DM. Cardioprotective actions of the novel adipocytokine visfatin. J Mol Cel Cardiol 2007; 42: S216-S217.